TD Asset Management Inc cut its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 15.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,642 shares of the company's stock after selling 3,664 shares during the period. TD Asset Management Inc's holdings in HealthEquity were worth $2,058,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in HQY. GAMMA Investing LLC increased its position in shares of HealthEquity by 25.9% during the first quarter. GAMMA Investing LLC now owns 1,571 shares of the company's stock worth $139,000 after purchasing an additional 323 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of HealthEquity by 24.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock worth $564,000 after purchasing an additional 1,265 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of HealthEquity by 17.3% during the first quarter. Janney Montgomery Scott LLC now owns 6,276 shares of the company's stock worth $555,000 after purchasing an additional 924 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of HealthEquity by 1.8% during the first quarter. State of Alaska Department of Revenue now owns 10,136 shares of the company's stock worth $895,000 after purchasing an additional 180 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its position in shares of HealthEquity by 6.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 75,206 shares of the company's stock worth $6,646,000 after purchasing an additional 4,614 shares in the last quarter. 99.55% of the stock is owned by institutional investors and hedge funds.
HealthEquity Price Performance
Shares of HQY opened at $96.00 on Wednesday. The firm has a market capitalization of $8.27 billion, a PE ratio of 58.18, a price-to-earnings-growth ratio of 1.34 and a beta of 0.47. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.23 and a quick ratio of 4.23. HealthEquity, Inc. has a 1-year low of $74.07 and a 1-year high of $116.65. The company's fifty day moving average price is $91.77 and its 200-day moving average price is $94.21.
HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Tuesday, September 2nd. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. HealthEquity had a net margin of 11.49% and a return on equity of 12.04%. The company had revenue of $325.80 million for the quarter, compared to analyst estimates of $320.68 million. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. On average, equities research analysts predict that HealthEquity, Inc. will post 2.32 EPS for the current year.
Insider Buying and Selling at HealthEquity
In other HealthEquity news, EVP Michael Henry Fiore sold 1,781 shares of the company's stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total value of $157,102.01. Following the sale, the executive vice president directly owned 49,795 shares of the company's stock, valued at approximately $4,392,416.95. This represents a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Delano Ladd sold 6,000 shares of the company's stock in a transaction on Friday, September 19th. The shares were sold at an average price of $94.11, for a total transaction of $564,660.00. Following the completion of the sale, the executive vice president directly owned 79,456 shares in the company, valued at approximately $7,477,604.16. The trade was a 7.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
HQY has been the topic of a number of recent analyst reports. Raymond James Financial reaffirmed a "strong-buy" rating and set a $120.00 price target (up from $115.00) on shares of HealthEquity in a research report on Tuesday, July 8th. Jefferies Financial Group upped their price target on HealthEquity from $130.00 to $134.00 and gave the stock a "buy" rating in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. upped their price target on HealthEquity from $125.00 to $126.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 3rd. Royal Bank Of Canada boosted their price objective on shares of HealthEquity from $109.00 to $110.00 and gave the company an "outperform" rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of HealthEquity in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $121.31.
View Our Latest Analysis on HQY
About HealthEquity
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Read More
Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.